You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 11, November 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE 39TH ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, WASHINGTON, DC, MAY 12 TO MAY 14, 1986-PART I
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Inhibition of Rat Colon Tumor Isograft Growth With Dequalinium Chloride

Ronald Bleday, MD; Michael J. Weiss, PhD; Ronald R. Salem, MD; Richard E. Wilson, MD; Lan Bo Chen, PhD; Glenn Steele, Jr, MD

Arch Surg. 1986;121(11):1272-1275.


Abstract

• In searching for a new approach to the systemic treatment of colorectal carcinoma, we have observed that certain lipophilic cationic compounds are accumulated and retained for a significantly longer period in the mitochondria of living carcinoma cells than in normal cells or sarcoma cells. We report the in vivo therapeutic effect of one of these compounds, dequalinium chloride, on the W163 rat colon carcinoma isograft, which grows rapidly in Wistar/Furth rats after primary tumor implantation, and which recurs rapidly after primary tumor resection. In the primary transplant model, tumors were implanted, and daily dequalinium chloride treatments were begun the following day in doses ranging from 1 to 10 mg/kg. In the recurrence model, isografts were implanted, allowed to grow for one week, and then all gross tumor was resected. Dequalinium chloride was administered in varying daily doses starting the day after resection. In both models, tumor was removed on day 11 after implantation or resection. At sublethal doses, dequalinium chloride significantly inhibited primary tumor growth to 60% that of controls and recurrent tumor growth to 50% that of controls. We propose that this unique biologic approach of targeting carcinoma mitochondria with lipophilic cationic compounds may provide a major new opportunity for treating colorectal carcinoma.

(Arch Surg 1986;121:1272-1275)



Author Affiliations

From the Laboratory of Cancer Biology, Department of Surgery, New England Deaconess Hospital (Drs Bleday, Weiss, Salem, and Steele), the Department of Surgery, Brigham and Women's Hospital (Drs Bleday and Wilson), and the Department of Pathology, Division of Cell Growth and Regulation, Dana-Farber Cancer Institute, Harvard Medical School (Dr Chen), Boston.


Footnotes

Accepted for publication July 31, 1986.

Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 13, 1986.

Reprint requests to Department of Surgery, New England Deaconess Hospital, 110 Francis St, Boston, MA 02115 (Dr Steele).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Potential Use of Cetrimonium Bromide as an Apoptosis-Promoting Anticancer Agent for Head and Neck Cancer
Ito et al.
Mol. Pharmacol. 2009;76:969-983.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.